RecruitingPhase 2NCT05483400
Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors
Studying Malignant germ cell tumor of the cervix uteri
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University Medical Center Groningen
- Principal Investigator
- Derk JA de Groot, MD PhDUniversity Medical Center Groningen
- Intervention
- Tiragolumab and atezolizumab(drug)
- Enrollment
- 97 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2027
Study locations (1)
- University Medical Center Groningen, Groningen, Netherlands
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05483400 on ClinicalTrials.govOther trials for Malignant germ cell tumor of the cervix uteri
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07519655Phase 1 Study of PF-08046033 in Advanced Solid TumorsPfizer
- RECRUITINGPHASE2NCT06177964Lerapolturev (PVSRIPO) in GBMDarell Bigner
- ACTIVE NOT RECRUITINGNCT02724488Selection Pressure and Evolution Induced by Immune Checkpoint Inhibitors and Other Immunologic TherapiesUniversity Health Network, Toronto
See all trials for Malignant germ cell tumor of the cervix uteri →